New Zealand markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.7800+0.0100 (+0.27%)
At close: 04:00PM EST
3.7200 -0.06 (-1.59%)
After hours: 07:18PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 322.17M
Enterprise value 494.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.88
Price/book (mrq)74.89
Enterprise value/revenue 6.81
Enterprise value/EBITDA -1.86

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-86.87%
S&P500 52-week change 314.07%
52-week high 339.4900
52-week low 33.5800
50-day moving average 35.9524
200-day moving average 314.3962

Share statistics

Avg vol (3-month) 32.26M
Avg vol (10-day) 31.3M
Shares outstanding 560.9M
Implied shares outstanding 6N/A
Float 820.08M
% held by insiders 10.83%
% held by institutions 174.65%
Shares short (30 Dec 2021) 48.65M
Short ratio (30 Dec 2021) 42.48
Short % of float (30 Dec 2021) 415.98%
Short % of shares outstanding (30 Dec 2021) 413.89%
Shares short (prior month 29 Nov 2021) 49.88M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin 0.00%
Operating margin (ttm)-348.66%

Management effectiveness

Return on assets (ttm)-66.52%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)72.68M
Revenue per share (ttm)2.75
Quarterly revenue growth (yoy)275.90%
Gross profit (ttm)78.22M
EBITDA -252.8M
Net income avi to common (ttm)-308.46M
Diluted EPS (ttm)-11.6890
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)103.67M
Total cash per share (mrq)3.57
Total debt (mrq)523.79M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.17
Book value per share (mrq)-13.53

Cash flow statement

Operating cash flow (ttm)-274.65M
Levered free cash flow (ttm)-208.22M